Schering-Plough (SGP) Comprehensive Income (Loss), Net of Tax, Attributable to Parent — Quarterly & Annual

Screener

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron PharmaceuticalsREGN

$1.25B-11.7%

EyePoint, Inc.EYPT

-$94.48M-58.7%

Tarsus Pharmaceuticals, Inc.TARS

-$18.81M+7.7%

RxSight, Inc.RXST

-$12.09M-1.4%

LENSAR, Inc.LNSR

$36.33M+233%

Halozyme TherapeuticsHALO

$234.79M+67.5%

Segments

By segment

Reporting Segment-$13.82M-56.6%

Other financials

Income statement

Operating income-$15.4M-108%

Net income-$13.8M-56.6%

EPS (diluted)-$0.69+82.6%

Balance sheet

Cash & equivalents$238.9M+312%

Total debt$1.6M—

Total equity$250.1M+463%

Total assets$258.4M—

Cash flow

Operating cash flow-$13.5M-65.2%

CapEx$676.0K+312%

Free cash flow-$14.2M-70.0%

Valuation

Market cap$846.2M+1.3%

Enterprise value$608.9M—

Returns & leverage

Return on equity-34.3%—

Debt / equity0×—

Current ratio38×—

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Schering-Plough’s 10-Q, filed May 14, 2026. Open the filing →

Filed: May 14, 2026, 4:30 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001778922-26-000035

FAQ

What is Schering-Plough's comprehensive income (loss), net of tax, attributable to parent?: Schering-Plough (SGP) reported comprehensive income (loss), net of tax, attributable to parent of -$13.82M in Q1 2026.
How has Schering-Plough's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?: Schering-Plough's comprehensive income (loss), net of tax, attributable to parent decreased by 56.6% year-over-year, from -$8.82M to -$13.82M.

Ask your AI about Schering-Plough's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk